We found that, although some genes appeared to be significantly different in both primary and metastatic tumors (LAMC2, NOTCH1, MET, IL6R, or STAT3), a significant percentage of the genes only had significant differences in metastatic tumors (Fig. 2d), suggesting that high MAP17 expression induces changes in cell expression that potentiates differentiation toward EMT and/or CSC phenotypes. The gene discussed is IL6R; the disease is metastatic neoplasm.